I am a
Home I AM A Search Login

Papers of the Week


Papers: 6 Feb 2021 - 12 Feb 2021


Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2021 Feb 10


Cephalalgia

Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.

Authors

Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD
Cephalalgia. 2021 Feb 10:333102421989601.
PMID: 33567891.

Abstract

Monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) have shown promising efficacy in randomised clinical trials for the prevention of episodic and chronic migraine, but no head-to-head comparisons with established treatments are available. We aimed to examine absolute differences in benefit-risk ratios between anti-CGRP mAbs, topiramate and propranolol for the prevention of episodic migraine and between anti-CGRP mAbs, topiramate and onabotulinumtoxinA for the prevention of chronic migraine using a likelihood to help versus harm analysis.